Treatment Outcomes With Unselected Autologous Tumor-Infiltrating Lymphocytes in Patients With Checkpoint Inhibition–Refractory Advanced Cutaneous Melanoma (ESMO) Post date September 26, 2021 ← Clinical Feasibility and Treatment Outcomes With Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients With Advanced Cutaneous Melanoma (AACR PPT) → Potent T-Cell Costimulation Mediated by a Novel Costimulatory Antigen Receptor (CoStAR) With Dual CD28/CD40 Signaling Domains to Improve Adoptive Cell Therapies (SITC)
Instil BioInstil Bio